NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

MaxCyte Inc (LSE: MXCT)

 
MXCT Technical Analysis
5
As on 26th Dec 2025 MXCT STOCK Price closed @ 1.61 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 160.12 & Strong Sell for SHORT-TERM with Stoploss of 343.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

MXCTSTOCK Price

Open 1.60 Change Price %
High 1.62 1 Day -146.08 -98.91
Low 1.56 1 Week -163.39 -99.02
Close 1.61 1 Month -164.39 -99.03
Volume 374564 1 Year -273.39 -99.41
52 Week High 405.00 | 52 Week Low 1.61
 
LSE UK Most Active Stocks
UKOG 0.01 0.00%
MIRI 0.01 0.00%
MSMN 0.02 0.00%
DEMG 0.02 -50.00%
SMDS 582.50 0.00%
DKE 0.15 0.00%
HE1 0.46 -2.13%
RBD 0.05 0.00%
RRR 0.02 0.00%
NNN 0.09 50.00%
 
LSE UK Top Gainers Stocks
BIOM 7.78 937.33%
0YY7 20.40 280.60%
SSIF 18.50 208.33%
CGW 55.03 107.66%
GILD 0.08 100.00%
GILD 0.08 100.00%
GILD 0.08 100.00%
0QTF 0.17 88.89%
CNN 65.00 85.71%
VENC 139.60 65.21%
 
LSE UK Top Losers Stocks
DNA 0.06 -99.90%
DNA 0.06 -99.90%
DNA 0.06 -99.90%
DNA 0.06 -99.90%
MXCT 1.61 -98.91%
MXCT 1.61 -98.91%
JPE 12.55 -98.66%
SPPC 0.15 -93.75%
AGM 1.00 -80.95%
AGM 1.00 -80.95%
 
 
MXCT
Daily Charts
MXCT
Intraday Charts
Whats New @
Bazaartrend
MXCT
Free Analysis
 
MXCT Important Levels Intraday
RESISTANCE1.73
RESISTANCE1.69
RESISTANCE1.67
RESISTANCE1.64
SUPPORT1.58
SUPPORT1.55
SUPPORT1.53
SUPPORT1.49
 
MXCT Forecast December 2025
4th UP Forecast189.94
3rd UP Forecast129.54
2nd UP Forecast92.21
1st UP Forecast54.87
1st DOWN Forecast-51.65
2nd DOWN Forecast-88.99
3rd DOWN Forecast-126.32
4th DOWN Forecast-186.72
 
MXCT Weekly Forecast
4th UP Forecast94.11
3rd UP Forecast64.44
2nd UP Forecast46.11
1st UP Forecast27.77
1st DOWN Forecast-24.55
2nd DOWN Forecast-42.89
3rd DOWN Forecast-61.22
4th DOWN Forecast-90.89
 
MXCT Forecast2025
4th UP Forecast784.51
3rd UP Forecast533.43
2nd UP Forecast378.23
1st UP Forecast223.03
1st DOWN Forecast-219.81
2nd DOWN Forecast-375.01
3rd DOWN Forecast-530.21
4th DOWN Forecast-781.29
 
 
MXCT Other Details
Segment EQ
Market Capital 766270016.00
Sector Healthcare
Industry Diagnostics & Research
Offical website >
 
MXCT Address
MXCT
 
MXCT Latest News
 
Your Comments and Response on MaxCyte Inc
 
MXCT Business Profile
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland. Address: 22 Firstfield Road, Gaithersburg, MD, United States, 20878
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service